TANDEM DIABETES CARE INC 8K

Tandem Diabetes Care, Inc. announced improved second quarter 2026 financial results, reaffirmed and updated aspects of its 2026 guidance, and reported key regulatory and commercial advances for its diabetes technology portfolio.

On August 6, 2026, Tandem Diabetes Care, Inc. reported its financial results for the quarter ended June 30, 2026, highlighting 6% year-over-year worldwide sales growth to $254.6 million, improved gross margin to 57%, a significantly reduced operating loss and net loss versus the prior-year period, positive adjusted EBITDA of $6.4 million, and increased pump shipments, while also reaffirming full-year 2026 revenue, margin, and adjusted EBITDA guidance and updating non-cash expense guidance downward; the company additionally noted regulatory and commercial milestones including an FDA 510(k) submission for Tandem Mobi tubeless capability, new FDA and CE Mark clearances for Control-IQ+ technology in pregnancy and type 2 diabetes, expanded sensor compatibility with Dexcom G7 and Abbott FreeStyle Libre 3 Plus, and the international rollout of Tandem Mobi.

Filing Facts

CIK

1438133

Ticker

-

Form

8K

Source Type

sec

Accession

0001438133-26-000124

Alert Tier

7